Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BI 1815368 in Healthy Japanese Males
NCT06494774Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1815368 in diabetic macular edema (DME) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related up to 26 days. Started Aug 2024; status: completed.
02
Drugs
BI 1815368
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06494774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494774.